| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonic Neoplasms | 6 | 2019 | 299 | 1.750 |
Why?
|
| Gene Expression Regulation, Neoplastic | 11 | 2021 | 756 | 1.280 |
Why?
|
| Colorectal Neoplasms | 10 | 2021 | 561 | 1.280 |
Why?
|
| Mutation | 10 | 2021 | 1213 | 1.270 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2020 | 231 | 0.920 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 332 | 0.760 |
Why?
|
| Cell Proliferation | 7 | 2021 | 1174 | 0.730 |
Why?
|
| Epigenesis, Genetic | 6 | 2020 | 163 | 0.680 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2019 | 2 | 0.670 |
Why?
|
| Human Embryonic Stem Cells | 1 | 2019 | 2 | 0.670 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2018 | 2 | 0.630 |
Why?
|
| Organoids | 1 | 2018 | 42 | 0.620 |
Why?
|
| Cisplatin | 1 | 2019 | 192 | 0.620 |
Why?
|
| DNA Methylation | 4 | 2020 | 193 | 0.590 |
Why?
|
| Membrane Proteins | 3 | 2013 | 617 | 0.590 |
Why?
|
| RNA, Small Interfering | 3 | 2018 | 434 | 0.570 |
Why?
|
| DNA Mutational Analysis | 4 | 2017 | 159 | 0.570 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 498 | 0.540 |
Why?
|
| Genes, p53 | 2 | 2020 | 41 | 0.510 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2017 | 300 | 0.460 |
Why?
|
| Melanoma | 3 | 2012 | 335 | 0.450 |
Why?
|
| Adenocarcinoma | 3 | 2008 | 475 | 0.440 |
Why?
|
| Loss of Heterozygosity | 1 | 2013 | 25 | 0.440 |
Why?
|
| 1-Phosphatidylinositol 4-Kinase | 1 | 2012 | 2 | 0.430 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2021 | 235 | 0.400 |
Why?
|
| Breast Neoplasms | 7 | 2022 | 1536 | 0.390 |
Why?
|
| Alleles | 4 | 2014 | 386 | 0.380 |
Why?
|
| RNA, Messenger | 3 | 2014 | 1664 | 0.370 |
Why?
|
| Cell Line, Tumor | 9 | 2020 | 1851 | 0.370 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2020 | 21 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2008 | 54 | 0.310 |
Why?
|
| Kidney Neoplasms | 2 | 2020 | 206 | 0.300 |
Why?
|
| Signal Transduction | 3 | 2020 | 2689 | 0.290 |
Why?
|
| Humans | 31 | 2022 | 68618 | 0.270 |
Why?
|
| Neoplasms | 4 | 2017 | 1667 | 0.260 |
Why?
|
| Transcriptome | 2 | 2017 | 164 | 0.230 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 1070 | 0.220 |
Why?
|
| Carcinogenesis | 3 | 2018 | 124 | 0.220 |
Why?
|
| DNA-Binding Proteins | 2 | 2020 | 700 | 0.210 |
Why?
|
| Transcription Factors | 2 | 2020 | 753 | 0.210 |
Why?
|
| Alcohol Oxidoreductases | 2 | 2020 | 31 | 0.200 |
Why?
|
| Calcium-Transporting ATPases | 1 | 2022 | 40 | 0.200 |
Why?
|
| Gene Silencing | 2 | 2020 | 137 | 0.200 |
Why?
|
| Genes, APC | 1 | 2021 | 15 | 0.200 |
Why?
|
| Brassica | 2 | 2018 | 13 | 0.190 |
Why?
|
| Isothiocyanates | 2 | 2018 | 10 | 0.190 |
Why?
|
| MAP Kinase Signaling System | 2 | 2012 | 247 | 0.190 |
Why?
|
| Cells, Cultured | 3 | 2019 | 2673 | 0.190 |
Why?
|
| Cell Transformation, Viral | 1 | 2020 | 26 | 0.190 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2020 | 13 | 0.190 |
Why?
|
| DNA Damage | 1 | 2022 | 190 | 0.190 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 23 | 0.180 |
Why?
|
| Keratinocytes | 1 | 2020 | 68 | 0.180 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2020 | 14 | 0.180 |
Why?
|
| Diet, Western | 1 | 2020 | 17 | 0.180 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 71 | 0.180 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2020 | 41 | 0.170 |
Why?
|
| Mitochondria | 2 | 2022 | 643 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 786 | 0.170 |
Why?
|
| Ovarian Neoplasms | 2 | 2016 | 267 | 0.170 |
Why?
|
| Repressor Proteins | 1 | 2020 | 183 | 0.170 |
Why?
|
| RNA-Binding Proteins | 1 | 2021 | 215 | 0.170 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 194 | 0.170 |
Why?
|
| Colon | 2 | 2018 | 168 | 0.170 |
Why?
|
| Female | 14 | 2022 | 38074 | 0.170 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 8 | 0.160 |
Why?
|
| Interferon Regulatory Factors | 1 | 2018 | 24 | 0.160 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2018 | 21 | 0.160 |
Why?
|
| Congresses as Topic | 1 | 2019 | 85 | 0.160 |
Why?
|
| Glutarates | 1 | 2018 | 6 | 0.160 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2018 | 6 | 0.160 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 122 | 0.150 |
Why?
|
| Anticarcinogenic Agents | 1 | 2018 | 52 | 0.150 |
Why?
|
| Interleukin-10 | 1 | 2018 | 144 | 0.150 |
Why?
|
| Calcium | 1 | 2022 | 929 | 0.150 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2018 | 114 | 0.150 |
Why?
|
| Middle Aged | 7 | 2019 | 21147 | 0.150 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 349 | 0.150 |
Why?
|
| Neoplasm Staging | 2 | 2013 | 800 | 0.150 |
Why?
|
| Colitis | 1 | 2018 | 156 | 0.150 |
Why?
|
| Neoplasm Metastasis | 3 | 2012 | 306 | 0.140 |
Why?
|
| Cell Movement | 3 | 2020 | 630 | 0.140 |
Why?
|
| Catechin | 1 | 2016 | 26 | 0.140 |
Why?
|
| Acetylglucosamine | 1 | 2017 | 46 | 0.140 |
Why?
|
| Drug Design | 1 | 2017 | 107 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 331 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 84 | 0.130 |
Why?
|
| Models, Genetic | 1 | 2016 | 161 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 88 | 0.130 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2015 | 56 | 0.130 |
Why?
|
| Trans-Activators | 1 | 2017 | 237 | 0.130 |
Why?
|
| Fibronectins | 2 | 2020 | 130 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2012 | 25 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 4 | 2021 | 852 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 411 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2017 | 194 | 0.120 |
Why?
|
| Gene Expression | 3 | 2020 | 770 | 0.120 |
Why?
|
| Young Adult | 3 | 2019 | 5717 | 0.120 |
Why?
|
| Animals | 11 | 2021 | 20881 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2020 | 824 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 304 | 0.110 |
Why?
|
| Mice | 8 | 2020 | 8474 | 0.110 |
Why?
|
| Allelic Imbalance | 1 | 2013 | 3 | 0.110 |
Why?
|
| Mutation Rate | 1 | 2013 | 11 | 0.110 |
Why?
|
| Aged | 5 | 2013 | 14862 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 4848 | 0.110 |
Why?
|
| Microsatellite Instability | 1 | 2013 | 39 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 1026 | 0.110 |
Why?
|
| Age Factors | 2 | 2019 | 1864 | 0.110 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2012 | 95 | 0.110 |
Why?
|
| Obesity | 1 | 2020 | 1076 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 300 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2017 | 954 | 0.100 |
Why?
|
| Amino Acid Sequence | 2 | 2012 | 1083 | 0.100 |
Why?
|
| Gene Frequency | 1 | 2012 | 207 | 0.100 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2012 | 231 | 0.100 |
Why?
|
| Receptors, Notch | 1 | 2012 | 15 | 0.100 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2012 | 44 | 0.100 |
Why?
|
| Lymphatic Metastasis | 2 | 2009 | 274 | 0.100 |
Why?
|
| Hedgehog Proteins | 1 | 2012 | 38 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 1 | 2012 | 129 | 0.100 |
Why?
|
| ras Proteins | 1 | 2012 | 102 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 627 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 710 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 223 | 0.090 |
Why?
|
| Base Sequence | 1 | 2012 | 1015 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 2 | 2004 | 332 | 0.090 |
Why?
|
| Genotype | 1 | 2012 | 786 | 0.090 |
Why?
|
| Genes, Neoplasm | 2 | 2007 | 18 | 0.090 |
Why?
|
| Anoikis | 1 | 2009 | 3 | 0.090 |
Why?
|
| NF-kappa B | 1 | 2012 | 432 | 0.090 |
Why?
|
| Age of Onset | 2 | 2020 | 188 | 0.080 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2009 | 22 | 0.080 |
Why?
|
| Muscle Proteins | 1 | 2009 | 94 | 0.080 |
Why?
|
| Adult | 5 | 2019 | 21403 | 0.080 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2009 | 28 | 0.080 |
Why?
|
| Microfilament Proteins | 1 | 2009 | 102 | 0.080 |
Why?
|
| Feedback, Physiological | 2 | 2021 | 38 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2009 | 152 | 0.080 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 508 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 1173 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2009 | 258 | 0.080 |
Why?
|
| Mice, Nude | 2 | 2020 | 294 | 0.080 |
Why?
|
| Sulfoxides | 2 | 2018 | 16 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 2 | 2020 | 615 | 0.070 |
Why?
|
| Consensus Sequence | 1 | 2006 | 20 | 0.070 |
Why?
|
| Prognosis | 2 | 2016 | 2093 | 0.070 |
Why?
|
| Male | 5 | 2013 | 37321 | 0.070 |
Why?
|
| Phenotype | 2 | 2020 | 947 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 492 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 375 | 0.060 |
Why?
|
| Bile Duct Neoplasms | 1 | 2004 | 39 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 2791 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2021 | 1692 | 0.060 |
Why?
|
| MicroRNAs | 2 | 2020 | 447 | 0.050 |
Why?
|
| Databases, Genetic | 2 | 2016 | 52 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2003 | 219 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 371 | 0.050 |
Why?
|
| ORAI1 Protein | 1 | 2022 | 1 | 0.050 |
Why?
|
| Secretory Pathway | 1 | 2022 | 6 | 0.050 |
Why?
|
| Adenosine Triphosphatases | 1 | 2022 | 83 | 0.050 |
Why?
|
| HT29 Cells | 1 | 2021 | 42 | 0.050 |
Why?
|
| Apoptosis | 2 | 2020 | 1641 | 0.050 |
Why?
|
| Respiration | 1 | 2022 | 91 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 82 | 0.050 |
Why?
|
| Calcium Signaling | 1 | 2022 | 97 | 0.050 |
Why?
|
| Wnt Signaling Pathway | 1 | 2021 | 57 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2020 | 12 | 0.050 |
Why?
|
| Cell Line, Transformed | 1 | 2020 | 100 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 2550 | 0.050 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 61 | 0.050 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 41 | 0.050 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2021 | 175 | 0.050 |
Why?
|
| Colforsin | 1 | 2020 | 42 | 0.050 |
Why?
|
| Semaphorins | 1 | 2020 | 7 | 0.050 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2020 | 20 | 0.040 |
Why?
|
| Sodium Glutamate | 1 | 2020 | 3 | 0.040 |
Why?
|
| High Fructose Corn Syrup | 1 | 2020 | 3 | 0.040 |
Why?
|
| Red Meat | 1 | 2020 | 10 | 0.040 |
Why?
|
| Flavoring Agents | 1 | 2020 | 24 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2020 | 160 | 0.040 |
Why?
|
| Food Handling | 1 | 2020 | 34 | 0.040 |
Why?
|
| Integrins | 1 | 2020 | 115 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2020 | 66 | 0.040 |
Why?
|
| Adolescent | 1 | 2012 | 8912 | 0.040 |
Why?
|
| Cytokines | 1 | 2004 | 866 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 5731 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 110 | 0.040 |
Why?
|
| Hypoxia | 1 | 2020 | 169 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2018 | 5 | 0.040 |
Why?
|
| Transfection | 1 | 2020 | 782 | 0.040 |
Why?
|
| Titanium | 1 | 2020 | 118 | 0.040 |
Why?
|
| Methylation | 1 | 2018 | 56 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 447 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2018 | 86 | 0.040 |
Why?
|
| Wound Healing | 1 | 2020 | 260 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 562 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 1038 | 0.040 |
Why?
|
| Cell Survival | 1 | 2020 | 901 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 2077 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 196 | 0.040 |
Why?
|
| Vegetables | 1 | 2018 | 76 | 0.040 |
Why?
|
| Mammary Glands, Animal | 1 | 2018 | 71 | 0.040 |
Why?
|
| Histones | 1 | 2018 | 111 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2020 | 370 | 0.040 |
Why?
|
| Maternal Exposure | 1 | 2018 | 75 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2018 | 117 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 170 | 0.040 |
Why?
|
| Coatomer Protein | 1 | 2017 | 4 | 0.040 |
Why?
|
| Ribosomal Proteins | 1 | 2017 | 18 | 0.040 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2017 | 20 | 0.040 |
Why?
|
| Gene Library | 1 | 2017 | 68 | 0.040 |
Why?
|
| Genome, Human | 2 | 2007 | 62 | 0.040 |
Why?
|
| Collagen | 1 | 2020 | 636 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 493 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2017 | 106 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 138 | 0.030 |
Why?
|
| Tea | 1 | 2016 | 23 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2007 | 208 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2017 | 238 | 0.030 |
Why?
|
| Diet | 1 | 2020 | 514 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 682 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2018 | 431 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 266 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 981 | 0.030 |
Why?
|
| Genes, myc | 1 | 2015 | 26 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2019 | 326 | 0.030 |
Why?
|
| Computational Biology | 2 | 2007 | 190 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 1033 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1603 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 307 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 649 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 792 | 0.030 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2012 | 3 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1465 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2012 | 20 | 0.030 |
Why?
|
| Inflammation | 1 | 2018 | 1030 | 0.030 |
Why?
|
| Pregnancy | 1 | 2018 | 2334 | 0.030 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2012 | 46 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 18 | 0.030 |
Why?
|
| Cadherins | 1 | 2012 | 93 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 147 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 4655 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2012 | 384 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2009 | 50 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 53 | 0.020 |
Why?
|
| Frameshift Mutation | 1 | 2009 | 8 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2009 | 15 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 196 | 0.020 |
Why?
|
| SOXE Transcription Factors | 1 | 2009 | 9 | 0.020 |
Why?
|
| Chromosomal Instability | 1 | 2009 | 14 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 282 | 0.020 |
Why?
|
| Genes, ras | 1 | 2009 | 46 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 254 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 113 | 0.020 |
Why?
|
| Glaucoma | 1 | 2009 | 50 | 0.020 |
Why?
|
| Necrosis | 1 | 2009 | 239 | 0.020 |
Why?
|
| Mesoderm | 1 | 2009 | 231 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 489 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 305 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 369 | 0.020 |
Why?
|
| Glioma | 1 | 2009 | 140 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2007 | 95 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2007 | 65 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2007 | 188 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 306 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2006 | 15 | 0.020 |
Why?
|
| United States | 1 | 2019 | 7367 | 0.020 |
Why?
|
| Survival Rate | 1 | 2009 | 1056 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 137 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 7029 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2007 | 307 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2004 | 73 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2004 | 93 | 0.010 |
Why?
|
| CA-19-9 Antigen | 1 | 2004 | 5 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2004 | 34 | 0.010 |
Why?
|
| Databases as Topic | 1 | 2004 | 49 | 0.010 |
Why?
|
| Cholangiocarcinoma | 1 | 2004 | 20 | 0.010 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2004 | 18 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2004 | 246 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 201 | 0.010 |
Why?
|
| Esophageal Neoplasms | 1 | 2004 | 150 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2004 | 74 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 1752 | 0.010 |
Why?
|
| Pancreas | 1 | 2004 | 225 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 320 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 507 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 1447 | 0.010 |
Why?
|
| Pancreatitis | 1 | 2004 | 279 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1174 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 1753 | 0.010 |
Why?
|